

Leprosy

Leprosy

- Leprosy (Hansen's disease) is a chronic granulomatous disease affecting skin and nerves.
- Caused by *Mycobacterium leprae*.
- A slow-growing mycobacterium that cannot be cultured in vitro.
- The clinical manifestations are determined by the degree of the patient's cell-mediated immunity towards *M. leprae*.
- High levels of CMI with elimination of leprosy bacilli produces tuberculoid leprosy.
- Absent CMI results in lepromatous leprosy.
- Complications arise due to nerve damage, immunological reactions and bacillary infiltration.

Leprosy

- People with leprosy are frequently stigmatized and using the word 'leper' is inappropriate.
- Untreated lepromatous patients discharge bacilli from the nose.
- Infection occurs through the nose, followed by hematogenous spread to skin and nerve.
- The incubation period is 2–5 years for tuberculoid cases and 8–12 years for lepromatous cases.
- Leprosy incidence peaks at 10–14 years.
- More common in males and in household contacts of leprosy cases.

Leprosy

❖ Pathogenesis :-

- **M. leprae has tropism for Schwann cells and skin macrophages.**
- **In tuberculoid leprosy, effective CMI controls bacillary multiplication and organized epithelioid granulomata form.**
- **In lepromatous leprosy, there is abundant bacillary multiplication, e.g. in Schwann cells and perineurium.**
- **Borderline tuberculoid, in patients with moderate CMI.**
- **Borderline lepromatous, in patients with little cellular response.**

Leprosy

❖ Pathogenesis :-

- Immunological reactions evolve as the immune response develops and the bacillary antigenic stimulus varies, particularly in borderline patients.
- Delayed hypersensitivity reactions produce type 1 (reversal) reactions, while immune complexes contribute to type 2 (erythema nodosum leprosum) reactions.
- HIV/leprosy co-infected patients have typical lepromatous and tuberculoid leprosy skin lesions and typical leprosy histology and granuloma formation.
- Even with low circulating CD4 counts, tuberculoid leprosy may be observed and there is not an obvious shift to lepromatous leprosy.

Leprosy

❖ Clinical features :-

➤ The cardinal features of leprosy includes the following ;-

❑ Skin lesions, typically anesthetic at tuberculoid end of spectrum.

❑ Thickened peripheral nerves.

❑ Acid-fast bacilli on skin smears or biopsy.

➤ Types of leprosy are:-

❑ Lepromatous leprosy.

❑ Tuberculoid leprosy.

Leprosy

❖ Clinical features :-

➤ Skin.

- ❑ The most common skin lesions are macules or plaques.
- ❑ Tuberculoid patients have few, hypopigmented lesions.
- ❑ Lepromatous leprosy, papules, nodules or diffuse infiltration of the skin.
- ❑ The earliest lesions are ill defined; gradually, the skin becomes infiltrated and thickened.
- ❑ Facial skin thickening leads to the characteristic leonine facies.

Leprosy

❖ Clinical features :-

➤ Anesthesia.

- ❑ The small dermal sensory and autonomic nerve fibers are damaged, causing localized sensory loss and loss of sweating.
- ❑ Can occur in the distribution of a damaged large peripheral nerve.
- ❑ A 'glove and stocking' sensory neuropathy is also common in lepromatous leprosy.

➤ Nerve damage.

- ❑ Peripheral nerve trunks are affected at 'sites of predilection' .
- ❑ Damage to peripheral nerve trunks produces characteristic signs with regional sensory loss and muscle dysfunction.
- ❑ All these nerves should be examined for enlargement and tenderness, and tested for motor and sensory function.
- ❑ The CNS is not affected.

Leprosy

❖ Clinical features :-

➤ Eye involvement.

- ❑ Blindness is a devastating complication for a patient with anesthetic hands and feet.
- ❑ Eyelid closure is impaired when the facial nerve is affected.
- ❑ Damage to the trigeminal nerve causes anesthesia of the cornea and conjunctiva.
- ❑ The cornea is then susceptible to trauma and ulceration.

➤ Other features.

- ❑ Many organs can be affected.
- ❑ Nasal collapse occurs secondary to bacillary destruction of the nasal cartilage and bone.
- ❑ Diffuse infiltration of the testes causes testicular atrophy and the acute orchitis that occurs with type 2 reactions.
- ❑ This results in azoospermia and hypogonadism.

Leprosy

❖ Leprosy reactions :-

☐ Type 1 (reversal) reactions.

- ✓ Occur in 30% of borderline patients.
- ✓ Are delayed hypersensitivity reactions.
- ✓ Skin lesions become erythematous.
- ✓ Peripheral nerves become tender and painful.
- ✓ Sudden loss of nerve function.
- ✓ May occur spontaneously, after starting treatment and also after completion of multidrug therapy (MDT).

Leprosy

❖ Leprosy reactions :-

❑ Type 2 (erythema nodosum leprosum, ENL) reactions.

- ✓ Due to immune complex deposition.
- ✓ Occur in BL and LL patients who produce antibodies and have a high antigen load.
- ✓ Manifest with malaise, fever and crops of small pink nodules on the face and limbs.
- ✓ Iritis and episcleritis are common.
- ✓ Other signs are acute neurites, lymphadenitis, orchitis, bone pain, dactylitis, arthritis and proteinuria.
- ✓ May continue intermittently for several years.

Leprosy

❖ Borderline cases :-

- Skin lesions are more numerous than in tuberculoid cases.
- more severe nerve damage and a risk of type 1 reactions.
- In borderline leprosy (BB) cases, skin lesions are numerous and vary in size, shape and distribution; annular lesions are characteristic and nerve damage is variable.
- In borderline lepromatous (BL) cases, there are widespread small macules in the skin and widespread nerve involvement; both type 1 and type 2 reactions occur.
- Pure neural leprosy occurs principally in India and accounts for 10% of patients.
- Asymmetrical involvement of peripheral nerve trunks and no visible skin lesions.
- On nerve biopsy, all types of leprosy have been found.

Leprosy

❖ Investigations :-

- The diagnosis is clinical, made by finding a cardinal sign of leprosy.
- Supported by detecting acid-fast bacilli in slit-skin smears or typical histology in a skin biopsy.
- Smears are useful for confirming the diagnosis and monitoring response to treatment.
- Neither serology nor PCR is sensitive or specific enough for diagnosis.

Leprosy

❖ Management :-

➤ Principles of leprosy treatment treatment

- ❑ Stop the infection with chemotherapy.
- ❑ Treat reactions.
- ❑ Educate the patient about leprosy.
- ❑ Prevent disability.
- ❑ Support the patient socially and psychologically.

Leprosy

❖ Management :-

➤ All leprosy patients require MDT with an approved first-line regimen.

➤ Rifampicin :-

✓ A potent bactericidal for *M. leprae*.

✓ Should always be given in combination with other antileprotics, since a single-step mutation can confer resistance.

➤ Dapsone:-

✓ Bacteriostatic.

✓ Commonly causes mild hemolysis and rarely anemia.

Leprosy

❖ Management :-

➤ Clofazimine :-

- ✓ A fat-soluble crystalline dye, weakly bactericidal for *M. leprae*.
- ✓ Skin discoloration (red to purple–black) and ichthyosis are troublesome side-effects, particularly on pale skins.

Leprosy

❖ Management :-

- The agents are now established second-line drugs;-
- ✓ Fluoroquinolones (pefloxacin and ofloxacin) are new bactericidal drugs against *M. leprae*.
- ✓ Minocycline and clarithromycin may also be used.
- Minocycline causes a grey pigmentation of skin lesions.
- The single-dose treatment is less effective than the conventional 6-month treatment for paucibacillary leprosy,
- Chloroquine can also be used.

Leprosy

❖ Management :-

- **Lepra reactions :-** are treated with Prednisolone for Type1 reaction, and prednisolone or thalidomide for Type2 reaction.

- **Patient education :-**
 - ❑ The patients should be informed that, after 3 days of chemotherapy, they are not infectious and can lead a normal social life.
 - ❑ It should emphasize that gross deformities are not inevitable.
 - ❑ Patients with anesthetic hands or feet need to avoid and treat burns or other minor injuries.
 - ❑ Good footwear is important.

- **Physiotherapy :-** helps maintain range of movement of affected muscles and neighboring joints.

Leprosy

❖ Prognosis :-

- **Untreated, Tuberculoid leprosy has a good prognosis; it may self-heal and peripheral nerve damage is limited.**
- **Untreated, Lepromatous leprosy (LL) is a progressive condition with high morbidity.**
- **Borderline patients are at risk of developing type 1 reactions, which may result in devastating nerve damage.**
- **After treatment, the majority of patients,, do well, with resolution of skin lesions, especially those who have no nerve damage at the time of diagnosis.**

Leprosy

❖ Prevention and control :-

- The previous strategy of centralized leprosy control campaigns has been superseded by integrated programmed, with primary health-care workers in many countries now responsible for case detection and provision of MDT.
- Is not yet clear how successful this will be, especially in the time-consuming area of disability prevention.
- BCG vaccination has been shown to give good but variable protection against leprosy; adding killed *M. leprae* to BCG does not enhance protection.

وطنی

انت



اغلی

من دمی